Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-20-012693
Filing Date
2020-05-15
Accepted
2020-05-15 17:25:26
Documents
57
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0320_relmadatherape.htm 10-Q 381262
2 OPINION OF SICHENZIA ROSS FERENCE LLP f10q0320ex5-1_relmada.htm EX-5.1 10408
3 SEVERANCE AND SEPARATION AGREEMENT, DATED APRIL 1, 2020, BY AND BETWEEN OTTAVIO f10q0320ex10-6_relmada.htm EX-10.6 42631
4 OPEN MARKET SALE AGREEMENTSM DATED AS OF MAY 15, 2020 BY AND BETWEEN RELMADA THE f10q0320ex10-7_relmada.htm EX-10.7 220806
5 CERTIFICATION f10q0320ex31-1_relmada.htm EX-31.1 11148
6 CERTIFICATION f10q0320ex31-2_relmada.htm EX-31.2 11342
7 CERTIFICATION f10q0320ex32-1_relmada.htm EX-32.1 4706
8 CERTIFICATION f10q0320ex32-2_relmada.htm EX-32.2 4574
15 GRAPHIC ex5-1_001.jpg GRAPHIC 10652
  Complete submission text file 0001213900-20-012693.txt   2859502

Data Files

Seq Description Document Type Size
9 XBRL INSTANCE FILE rlmd-20200331.xml EX-101.INS 307533
10 XBRL SCHEMA FILE rlmd-20200331.xsd EX-101.SCH 45083
11 XBRL CALCULATION FILE rlmd-20200331_cal.xml EX-101.CAL 39595
12 XBRL DEFINITION FILE rlmd-20200331_def.xml EX-101.DEF 160768
13 XBRL LABEL FILE rlmd-20200331_lab.xml EX-101.LAB 319510
14 XBRL PRESENTATION FILE rlmd-20200331_pre.xml EX-101.PRE 226294
Mailing Address 880 3RD AVENUE, 12TH FLOOR NEW YORK NY 10022
Business Address 880 3RD AVENUE, 12TH FLOOR NEW YORK NY 10022 646 876 3459
RELMADA THERAPEUTICS, INC. (Filer) CIK: 0001553643 (see all company filings)

EIN.: 455401931 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39082 | Film No.: 20886927
SIC: 2834 Pharmaceutical Preparations